Understanding the Market | GIANT BIOGENE falls over 3% again, down more than 20% from historical highs, controversy over the ingredients of its KefuMei products continues to escalate
I'm PortAI, I can summarize articles.
GIANT BIOGENE's stock price fell over 3% again, retreating more than 20% from its historical high, currently reported at HKD 65.9, with a trading volume of HKD 982 million. The controversy over the ingredients of its product KefuMei continues to escalate, with a statement released on June 1 apologizing to the testing agency and stating that they will pursue legal responsibility for the rumor-mongers. Huaxi Biology expressed opposition to the name game regarding this controversy, emphasizing product quality issues. Morgan Stanley pointed out that GIANT BIOGENE will release more evidence from independent institutions to clarify consumer concerns
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Zhitong The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments